ABSTRACT
Cost effectiveness analyses (CEAs) are widely used to evaluate the opportunity cost of health care investments. However, few functions that take equity concerns into account are available for such CEA methods, and these concerns are therefore at risk of being disregarded. Among the functions that have been developed, most focus on the distribution of health gains, as opposed to the distribution of lifetime health. This is despite the fact that there are good reasons to give higher priority to individuals and groups with a low health adjusted life expectancy. Also, an even distribution of health gains may imply an uneven distribution of lifetime health.
We develop a systematic and explicit approach that allows for the inclusion of lifetime health concerns in CEAs, by creating a new priority weight function, PW=α+(t-γ)·C·e-β·(t-γ), where t is the health measure. PW has several desirable properties. First, it is continuous and smooth, ensuring that people with similar health characteristics are treated alike. Second, it is flexible regarding shape and outcome measure, so that a broad range of values may be modelled.
Third, the coefficients have distinct roles. This allows for the easy manipulation of the PW’s shape. In order to demonstrate how PW may be applied, we use data from a previous study and estimated the coefficients of PW based on two approaches.
The first considers the mean weights assigned by the respondents:
PWmean=-0.42+(t+22.2)·0.27·e-0.031·(t+22.2).
The second considers the median weights:
PWmedian=0.79+(t+8.85)·0.17·e-0.053·(t+8.85).
This illustrates that our framework allows for the estimation of PWs based on empirical data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding has been received from a third party.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Not Applicable
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Footnotes
Other authors: Frode Lindemark: frode.lindemark{at}igs.uib.no, Kjell Arne Johansson: kjell.johansson{at}igs.uib.no
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.